Mizuho lowered the firm’s price target on Axsome Therapeutics to $108 from $112 and keeps a Buy rating on the shares. The target drop is based on pushing out launch timelines for AXS-05 in Alzheimer’s disease agitation by one year to the second half of 2026, and increasing spending estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics price target lowered to $123 from $126 at RBC Capital
- Axsome Therapeutics price target lowered to $107 from $111 at UBS
- Axsome Therapeutics price target raised to $125 from $110 at Guggenheim
- Axsome Therapeutics Inc. Reported Earnings. Did it Beat Estimates?
- Axsome Therapeutics Updates Corporate Presentation Online
